Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches

Affiliations

Editorial

Valentina Mazza et al. J Thorac Dis. 2016 Oct.

. 2016 Oct;8(10):E1348-E1350.

doi: 10.21037/jtd.2016.10.99.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N. Vansteenkiste JF, et al. Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27. Lancet Oncol. 2016. PMID: 27132212 Clinical Trial.

1. Raez LE, Fein S, Podack ER. Lung cancer immunotherapy. Clin Med Res 2005;3:221-8. 10.3121/cmr.3.4.221 - DOI - PMC - PubMed
1. Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016;5:1-20. - PMC - PubMed
1. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31. 10.1016/S0140-6736(09)60569-9 - DOI - PubMed
1. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27. 10.1093/annonc/mdh031 - DOI - PubMed
1. Ottevaere A, De Brucker N, Vansteenkiste J. How Do We Move Forward with Vaccines in Lung Cancer? 2015;11:92-3.